(secondQuint)Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF).

 The purpose of Phase 1 is to determine a maximum tolerated dose (MTD) for KB004 when administered to subjects with hematologic malignancies who meet the entry criteria.

 Phase 1 has completed enrollment July of 2014, the recommended Phase 2 dose is 250 mg.

 AML 20 mg Cohort completed enrollment Dec 2014.

 The purpose of Phase 2 is to characterize preliminary clinical activity.

 The Phase 2 portion of the study consists of two parts: - Part A: Subjects with AML or MDS who meet the entry criteria - Part B: Subjects with MF who meet the entry criteria.

 Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)@highlight

This is a global, multicenter, open-label, repeat-dose, Phase 1/2 study consisting of a Dose Escalation Phase (Phase 1) and a Cohort Expansion Phase (Phase 2).

 In both phases, KB004 will be administered by IV infusion once weekly as part of a 21-day dosing cycle.

